Literature DB >> 22911111

Loss of heterozygosity (LOH) profiles--validated risk predictors for progression to oral cancer.

Lewei Zhang1, Catherine F Poh, Michele Williams, Denise M Laronde, Ken Berean, Pamela J Gardner, Huijun Jiang, Lang Wu, J Jack Lee, Miriam P Rosin.   

Abstract

A major barrier to oral cancer prevention has been the lack of validated risk predictors for oral premalignant lesions (OPL). In 2000, we proposed a loss of heterozygosity (LOH) risk model in a retrospective study. This paper validated the previously reported LOH profiles as risk predictors and developed refined models via the largest longitudinal study to date of low-grade OPLs from a population-based patient group. Analysis involved a prospective cohort of 296 patients with primary mild/moderate oral dysplasia enrolled in the Oral Cancer Prediction Longitudinal Study. LOH status was determined in these OPLs. Patients were classified into high-risk or low-risk profiles to validate the 2000 model. Risk models were refined using recursive partitioning and Cox regression analyses. The prospective cohort validated that the high-risk lesions (3p and/or 9p LOH) had a 22.6-fold increase in risk (P = 0.002) compared with low-risk lesions (3p and 9p retention). Addition of another 2 markers (loci on 4q/17p) further improved the risk prediction, with five-year progression rates of 3.1%, 16.3%, and 63.1% for the low-, intermediate-, and high-risk lesions, respectively. Compared with the low-risk group, intermediate- and high-risk groups had 11.6-fold and 52.1-fold increase in risk (P < 0.001). LOH profiles as risk predictors in the refined model were validated in the retrospective cohort. Multicovariate analysis with clinical features showed LOH models to be the most significant predictors of progression. LOH profiles can reliably differentiate progression risk for OPLs. Potential uses include increasing surveillance for patients with elevated risk, improving target intervention for high-risk patients while sparing a large number of low-risk patients from needless screening and treatment.

Entities:  

Mesh:

Year:  2012        PMID: 22911111      PMCID: PMC3793638          DOI: 10.1158/1940-6207.CAPR-12-0173

Source DB:  PubMed          Journal:  Cancer Prev Res (Phila)        ISSN: 1940-6215


  25 in total

Review 1.  Intrinsic tumour suppression.

Authors:  Scott W Lowe; Enrique Cepero; Gerard Evan
Journal:  Nature       Date:  2004-11-18       Impact factor: 49.962

2.  Frequent microsatellite alterations at chromosomes 9p21 and 3p14 in oral premalignant lesions and their value in cancer risk assessment.

Authors:  L Mao; J S Lee; Y H Fan; J Y Ro; J G Batsakis; S Lippman; W Hittelman; W K Hong
Journal:  Nat Med       Date:  1996-06       Impact factor: 53.440

3.  Leukoplakia, dysplasia, and malignant transformation.

Authors:  S Silverman; M Gorsky; G E Kaugars
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol Endod       Date:  1996-08

Review 4.  The regulation of INK4/ARF in cancer and aging.

Authors:  William Y Kim; Norman E Sharpless
Journal:  Cell       Date:  2006-10-20       Impact factor: 41.582

Review 5.  What has senescence got to do with cancer?

Authors:  Goberdhan P Dimri
Journal:  Cancer Cell       Date:  2005-06       Impact factor: 31.743

Review 6.  Oral white lesions with special reference to precancerous and tobacco- related lesions: conclusions of an international symposium held in Uppsala, Sweden, May 18-21 1994. International Collaborative Group on Oral White Lesions.

Authors:  T Axéll; J J Pindborg; C J Smith; I van der Waal
Journal:  J Oral Pathol Med       Date:  1996-02       Impact factor: 4.253

Review 7.  Reducing the "risk" of chemoprevention: defining and targeting high risk--2005 AACR Cancer Research and Prevention Foundation Award Lecture.

Authors:  Scott M Lippman; J Jack Lee
Journal:  Cancer Res       Date:  2006-03-15       Impact factor: 12.701

8.  Carcinoma and dysplasia in oral leukoplakias in Taiwan: prevalence and risk factors.

Authors:  Jang-Jaer Lee; Hsin-Chia Hung; Shi-Jung Cheng; Yi-Jane Chen; Chun-Pin Chiang; Bu-Yuan Liu; Jiiang-Huei Jeng; Hao-Hueng Chang; Ying-Shiung Kuo; Wan-Hong Lan; Sang-Heng Kok
Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol Endod       Date:  2006-01-19

9.  Malignant transformation of oral leukoplakia: a follow-up study of a hospital-based population of 166 patients with oral leukoplakia from The Netherlands.

Authors:  K P Schepman; E H van der Meij; L E Smeele; I van der Waal
Journal:  Oral Oncol       Date:  1998-07       Impact factor: 5.337

Review 10.  Regulation of the INK4b-ARF-INK4a tumour suppressor locus: all for one or one for all.

Authors:  Jesús Gil; Gordon Peters
Journal:  Nat Rev Mol Cell Biol       Date:  2006-09       Impact factor: 94.444

View more
  45 in total

1.  Ex vivo confocal imaging with contrast agents for the detection of oral potentially malignant lesions.

Authors:  S El Hallani; C F Poh; C E Macaulay; M Follen; M Guillaud; P Lane
Journal:  Oral Oncol       Date:  2013-02-12       Impact factor: 5.337

2.  Cost-Effectiveness Analysis of Using Loss of Heterozygosity to Manage Premalignant Oral Dysplasia in British Columbia, Canada.

Authors:  Ian Cromwell; Dean A Regier; Stuart J Peacock; Catherine F Poh
Journal:  Oncologist       Date:  2016-07-11

Review 3.  The microRNA signatures: aberrantly expressed microRNAs in head and neck squamous cell carcinoma.

Authors:  Keiichi Koshizuka; Toyoyuki Hanazawa; Ichiro Fukumoto; Naoko Kikkawa; Yoshitaka Okamoto; Naohiko Seki
Journal:  J Hum Genet       Date:  2016-08-25       Impact factor: 3.172

Review 4.  Prognostic factors, predictive markers and cancer biology: the triad for successful oral cancer chemoprevention.

Authors:  Jose Augusto Monteiro de Oliveira Novaes; William N William
Journal:  Future Oncol       Date:  2016-06-22       Impact factor: 3.404

5.  Targeting the epidermal growth factor receptor for head and neck cancer chemoprevention.

Authors:  Milena P Mak; William N William
Journal:  Oral Oncol       Date:  2014-01-10       Impact factor: 5.337

6.  Notch1 mutations are drivers of oral tumorigenesis.

Authors:  Evgeny Izumchenko; Kai Sun; Sian Jones; Mariana Brait; Nishant Agrawal; Wayne Koch; Christine L McCord; David R Riley; Samuel V Angiuoli; Victor E Velculescu; Wei-Wen Jiang; David Sidransky
Journal:  Cancer Prev Res (Phila)       Date:  2014-11-18

Review 7.  PPARγ in head and neck cancer prevention.

Authors:  Mauricio Burotto; Eva Szabo
Journal:  Oral Oncol       Date:  2014-01-13       Impact factor: 5.337

Review 8.  Molecular cancer prevention: Current status and future directions.

Authors:  Karen Colbert Maresso; Kenneth Y Tsai; Powel H Brown; Eva Szabo; Scott Lippman; Ernest T Hawk
Journal:  CA Cancer J Clin       Date:  2015-08-18       Impact factor: 508.702

Review 9.  Essentials of oral cancer.

Authors:  César Rivera
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01

10.  Predicting progression of oral dysplasia--response.

Authors:  Miriam P Rosin; Lewei Zhang; Li Mao
Journal:  Cancer Prev Res (Phila)       Date:  2013-04-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.